Delving into the Latest Updates on OncoVista Innovative Therapies, Inc. with Synapse

This is a two-part, open-label, Phase I/II study in subjects with relapsed or refractory TdT-positive leukemia for which no standard therapies are expected to result in durable remission.

开始日期2008-06-01

申办/合作机构

OncoVista, Inc.

[+1]

100 项与 OncoVista Innovative Therapies, Inc. 相关的临床结果

登录后查看更多信息

0 项与 OncoVista Innovative Therapies, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 OncoVista Innovative Therapies, Inc. 相关的文献（医药）

2016-02-01·Investigational New Drugs3区 · 医学

Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin

3区 · 医学

Article

作者: Weis, Alexander L ; Bakos, Tamas ; Banerjee, Asok ; Yeh, Lee-Chuan C ; Prasad, Veena ; Lee, John C ; Yeh, I-Tien ; Tuszynski, Jack A ; Ludueña, Richard F

The subunit protein of microtubules is tubulin, which has been the target for some of the most successful and widely used anti-tumor drugs. Most of the drugs that target tubulin bind to the β subunit. There are many isotypes of β-tubulin and their distributions differ among different tissues. The βIII isotype is over-expressed in many tumors, particularly those that are aggressive, metastatic, and drug resistant. We have previously reported the design and synthesis of a series of compounds to fit the colchicine site on βIII but not on the other isotypes. In the current study, we tested the toxicity and the anti-tumor activity of one of these compounds, CH-35, on the human breast tumor MDA-MB-231 over-expressing βIII in a xenogeneic mouse model. We found that CH-35 was as toxic as Taxol® in vivo. Although the βIII-over-expressing cells developed into very fast-growing tumors, CH-35 was more effective against this tumor than was Taxol. Our results suggest that CH-35 is a promising candidate for future drug development.

2

项与 OncoVista Innovative Therapies, Inc. 相关的新闻（医药）

2012-07-10

·BioSpace

FDA Approves OncoVista Innovative Therapies, Inc.'s Phase I Clinical Trial of New Drug Candidate (OVI-117) for Solid Tumors

SAN ANTONIO, TX--(Marketwire - July 10, 2012) - OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies, announced today that the US Food and Drug Administration (FDA) granted approval for the Company's investigational new drug (IND) application for its L-nucleoside conjugate (OVI-117) drug candidate. "The FDA's swift approval of our IND provides validation of OncoVista's mission to be a leader in the development of more efficacious and less toxic targeted cancer therapies," said Alexander Weis, PhD., Chairman, President and CEO of OncoVista. This will allow the Company to build and enhance our drug portfolio to the benefit of shareholders and more importantly, patients. The founding mission of OncoVista is to develop more effective and less toxic drugs for cancer. This is an important milestone towards that mission. About OVI-117 OVI-117, a derivative of FdUMP/5-FU, is a Thymidylate Synthase (TS) inhibitor with enhanced pharmacological properties resulting in the retention of efficacy and the reduction of toxicity. It has particular promise for colon, breast, gastric and prostate tumors. About OncoVista Innovative Therapies Texas-based OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), founded in 2004, is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies which are more efficacious and less toxic. For additional information, please visit OncoVista's corporate website at Forward-Looking Statements: A number of statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. These risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. COMPANY CONTACT: Michael Moloney Chief Operating Officer (210) 677-6000

2009-12-03

·BioSpace

OncoVista Innovative Therapies, Inc. Reinstated on the OTC Bulletin Board

SAN ANTONIO--(BUSINESS WIRE)--OncoVista Innovative Therapies, Inc. (OTCBB: OVIT) announced today that its application for reinstatement on the Over-The-Counter Bulletin Board has been accepted.

创新药

100 项与 OncoVista Innovative Therapies, Inc. 相关的药物交易

登录后查看更多信息

100 项与 OncoVista Innovative Therapies, Inc. 相关的转化医学

登录后查看更多信息